Few Switch Employer Health Plans for Better Quality, Lower Costs
Less than 2.5 percent of nonelderly Americans in 2010 with employer coverage — about the same proportion as in 2003 — initiated a change in health plans to reduce their health insurance costs or get a better quality plan, according to a national study by the Center for Studying Health System Change for the nonpartisan, nonprofit National Institute for Health Care Reform.
Overall, about one in eight (12.8 percent) people younger than 65 with employer coverage switched health plans in 2010 — down from one in six (17.2 percent) in 2003, the study found.
As was true in 2003, about 5 percent of people with employer coverage switched plans in 2010 because of a job change. However, the proportion of people changing plans for other reasons fell from 12 percent in 2003 to 7.5 percent in 2010.
Of the 7.5 percent who changed plans in 2010 for reasons other than a job change, most switched because of a change in their employer's benefit offerings (62.7 percent). The other third of plan changes were worker initiated — usually to obtain a less expensive plan or better quality plan. Among all nonelderly people with employer coverage, 2.3 percent changed plans in 2010 in search of better quality or lower costs.
"These findings suggest that consumer choice plays a relatively small role in health plan switching, with most changes resulting from job changes or changes in employers' plan offerings," said study author Peter J. Cunningham, HSC senior fellow and director of quantitative research.
The decrease in plan switching parallels a decrease in employer-sponsored coverage among workers in small and medium-sized businesses who change plans more frequently compared with workers in larger firms, according to the study. The rate of employer coverage among workers in firms with fewer than 500 workers decreased from 63 percent in 2003 to 54 percent in 2010, while employer coverage among workers in larger firms—500 workers or more—held steady at about 83 percent.
The rate at which people change health plans is one indicator of the degree of choice and competition in health insurance markets, which many believe are essential to reduce health care costs and improve quality. For people with employer-sponsored health insurance, opportunities to change health plans are largely constrained by whatever choices employers offer.
Previous research shows about half of workers with employer coverage are offered a single plan by their employer, while only about 15 percent have a choice of three or more plans.
National health reform may create opportunities to increase plan choice among people with employer-sponsored coverage, particularly those in small firms, resulting in more frequent switching, the study noted. However, a potential downside of more switching is less stable patient-provider relationships, such as in a medical home.
The study's findings are detailed in a NIHCR Research Brief, "Few Americans Switch Employer Health Plans for Better Quality, Lower Costs," available online at www.nihcr.org/Health-Plan-Switching.
People May Think It's More Vital to Take Meds if They're Cheap
A study from the W. P. Carey School of Business at Arizona State University shows consumers believe prices for lifesaving products are based on need and not profit. Therefore, they often assume their risk of getting a serious illness is higher when the medicine is less expensive, and they're also more likely to plan to get the treatment, including flu shots.
"We find that people have a fundamental belief that everyone should have access to lifesaving care, such as vaccines, doctor's visits, screening tests like mammograms, and cancer treatments," says Assistant Professor Adriana Samper of the W. P. Carey School of Business. "Nobody wants anyone to die because they didn't have the resources to cover the treatment. Therefore, they believe communal pricing (based on need), rather than the normal market pricing for other goods, applies in these situations. They expect medicine for a serious illness to be inexpensive."
Samper's new marketing study, co-authored with Assistant Professor Janet Schwartz of Tulane University, will appear in the April edition of the Journal of Consumer Research. In a series of experiments, the researchers demonstrated several interesting points about medication pricing, and those points held true, even if insurance — not the consumer — was going to pay for the treatments.
In the first experiment, participants in an online study were asked to evaluate 10 products and services based on whether they were priced for "communal" purposes or market value. Vaccines, doctor's visits and drugs used to prevent serious illnesses all ranked as being driven by communal pricing, while items like tax-preparation services, restaurant menu items and home electronics all ranked as market-driven.
In the next experiment, online participants were asked about a fictitious cream described as either preventing skin cancer or preventing age spots. The cream was also offered at a low price of $25 or a high price of $250. Price had no effect on attitudes toward the cosmetic cream, but when the skin-cancer treatment was only $25, respondents believed they needed it more — that they were at higher risk for the disease.
"We see the same thing for a flu shot," says Samper. "People are more concerned about getting the disease and addressing prevention if the vaccine is cheaper. That's an important note for health officials during our especially tough flu season right now."
A third experiment showed participants an ad for the same cream, with the same image, but slightly different versions of text, again reflecting whether the cream was for skin-cancer prevention or cosmetic purposes. The two different price points were offered in each case. Consumers were much more likely to keep reading the ad and planned to pursue the treatment in the case where the cream was for skin cancer and the price was lower. This happened even when insurance was going to pay for the cream at either price.
"This implies a possible problem with the recent push for price transparency," Samper says. "In some cases, high prices may signal lower self-risk, and people may not think it's important to get needed treatments just because the cost is high."
In the last experiment, the researchers tested the effects of different types of messages meant to encourage people to get flu shots. They used the two prices again and also varied whether the flu's consequences were described as self-focused — such as missing work or paying medical bills if you got the flu — or societally focused — such as getting other people sick or hurting economic productivity with the flu's spread. Very clearly, individuals again increased their assumption of risk and intentions to get the vaccine in response to lower price, but only when the message focused on personal consequences of the flu.
"Therefore, public health officials should take note: Ads emphasizing the protection of other people do not appear to convince people to get vaccinated," says Samper. "People respond best to messages that emphasize how illness will personally affect them."
The full study can be found at http://www.jstor.org/stable/info/10.1086/668639.